Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Pertuzumab 帕妥珠单抗

Pertuzumab (Pertuzumab, also known as 2C4, trade name Perjeta) is a monoclonal antibody. It is the first monoclonal antibody called a “HER dimerization inhibitor.” By binding to HER2, it blocks the heterodimerization of HER2 with other HER receptors, thereby slowing down tumor growth [1]. Pertuzumab was approved by the US FDA on June 8, 2012, for the treatment of HER2-positive metastatic breast cancer [2].

Share:

Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.